Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
so i think i place another order near $ 1,40
gap closed now? or what?
think i will add next week again - possibly i reach 200k - or i try a stop buy limit - hmmmmmm......
Pfffff.... i´am back to 115! Dont know reall why - maybe because it´s too sticky in Austria :)
Only 110 now!!!!! We have lost 5 ?????
http://www.clinicaltrials.gov/ct2/show/NCT01999673?term=bavituximab&rank=8
140k volume from 1,67 to 1,60 and than another 140k volumen from 1,62 to 1,55
FDA grants Roche Holding AG's Genentech's Avastin priority review for recurrent platinum-resistant ovarian cancer
22-Jul-2014 07:25
Roche Holding AG:
• Genentech, a member of the Roche Group says that U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license application (sBLA)
• And granted priority review for Avastin (bevacizumab) plus chemotherapy for treatment of women with recurrent platinum-resistant ovarian cancer
• Designation of priority review status is granted to medicines that FDA believes have potential to provide 'significant improvements in safety or effectiveness of treatment, diagnosis, or prevention of serious conditions when compared to standard applications
• SBLA for Avastin plus chemotherapy for recurrent platinum-resistant ovarian cancer is based on data from Phase III AURELIA trial with FDA action date of Nov. 19
You forgott that:
http://www.ilca-online.org/
:)
Eastern Capital:
TOP 10 HOLDINGS (AS OF LATEST FILING) View All
1.
Alnylam Pharmaceuticals Inc ALNY.O
29.48% of portfolio, 4.93m shares +0.70m shares
Latest Filing Date 31-Dec-2012
2.
XOMA Corp XOMA.O
18.76% of portfolio, 6.85m shares +0.55m shares
Latest Filing Date 12-Feb-2014
3.
Portola Pharmaceuticals Inc PTLA.O
15.84% of portfolio, 1.88m shares +0.01m shares
Latest Filing Date 31-Dec-2013
4.
Spectrum Pharmaceuticals Inc SPPI.O
10.66% of portfolio, 4.74m shares +4.74m shares
Latest Filing Date 28-Apr-2014
5.
Cytokinetics Inc CYTK.O
9.31% of portfolio, 2.88m shares +0.50m shares
Latest Filing Date 28-Feb-2014
6.
Verastem Inc VSTM.O
4.27% of portfolio, 1.14m shares Unchanged
Latest Filing Date 31-Dec-2013
7.
Resverlogix Corp RVX.TO
3.87% of portfolio, 14.97m shares Unchanged
Latest Filing Date 03-Jul-2014
8.
Peregrine Pharmaceuticals Inc PPHM.O
3.43% of portfolio, 7.92m shares +0.50m shares
Latest Filing Date 31-Dec-2012
9.
Ibio Inc IBIO.K
2.54% of portfolio, 21.96m shares +7.50m shares
Latest Filing Date 15-Oct-2013
10.
Cyclacel Pharmaceuticals Inc CYCC.O
1.38% of portfolio, 1.25m shares +1.25m shares
Latest Filing Date 28-May-2013
Roche CEO plans to steer clear of big acquisitions
19-Jul-2014 09:23
ZURICH, July 19 (Reuters) - Roche ROG.VX plans to steer clear of the wave of big takeovers sweeping through the healthcare industry and focus instead on small acquisitions and partnerships, the Swiss drugmaker's chief executive said in an interview published on Saturday.
"We're sticking to our previous strategy. This includes targeted, small acquisitions and partnerships like the ones we have carried out in recent months," Severin Schwan told business newspaper Finanz und Wirtschaft.
Several multi-billion dollar deals and bids over the past few months have made 2014 a busy year for healthcare acquisitions as companies look to build scale in leading businesses or slash their tax bill, a tactic known as inversion.
On Friday, U.S. drugmaker AbbVie Inc ABBV.N finally clinched Dublin-based Shire Plc SHP.L in a $55 billion deal that will give it access to expensive medicines to treat rare diseases.
But since acquiring the remainder of U.S. biotech company Genentech for $46.8 billion in 2009, Roche has earned a reputation as a disciplined acquirer, prepared to walk away from potential deals rather than overpay.
It has snapped up a couple of smaller diagnostic companies so far this year and earlier this month agreed to buy privately-held U.S. biotech company Seragon Pharmaceuticals for $1.7 billion. (Full Story)
Roche's criteria include whether a product or a technology has the potential to improve the standard of care and whether it fits into the company's two business areas of pharmaceuticals and diagnostics, Schwan told the paper.
High valuations of companies in the healthcare industry have dampened Roche's appetite for big deals, he added.
"We take a look at everything. But at present the calculations only add up in the fewest cases," Schwan said.
"We have to weigh up internal and external opportunities. It can't be that we have to put important internal opportunities on ice because of too-expensive acquisitions."
Pphmp - high volume today
108 !!!! uuuppppppppppp
http://www.clinicaltrials.gov/ct2/show/NCT01999673?term=bavituximab&rank=8
Hi CP,
is that the right date???
http://www.ilca2014.org/
What is ECN???
thx CP :)
Maybe this ist not new for you!
http://www.forbes.com/sites/matthewherper/2014/05/07/is-this-how-well-cure-cancer/
On Friday, shares in Peregrine Pharmaceuticals Inc. fluctuated between $1.83
and $1.92 before ending the session 3.78% higher at $1.92. Peregrine
Pharmaceuticals Inc.'s stock reported a trading volume of 2.57 million shares,
above its three months average volume of 1.62 million shares. Peregrine
Pharmaceuticals Inc.'s shares have advanced 8.47% in the previous three trading
sessions, 3.23% in the last three months and 38.13% on YTD basis. The stock is
trading above its 50-day and 200-day moving averages of $1.79 and $1.65,
respectively. Moreover, shares of the company have an RSI of 60.70. Sign up
today to read free research on PPHM at:
http://www.investor-edge.com/4325-PPHM-30Jun2014.pdf
We have 91 Locations!!!! up in the air :)
Added some more at 1,86 - nice weekend all pphm's
Thx for that Link - hutschi from Austria nice chart too!
but Austria is missing!
89 study loc. !
hight volume at the ende of dthe day :)
Yes - nice start!
But: why is that so important???
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, CA--(Marketwired - Jun 10, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on July 1, 2014 to holders of record at the close of business on June 20, 2014.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from April 1, 2014 through June 30, 2014. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com
02-Jun-2014 13:33 - PHASE 3 STUDY EVALUATING YERVOY® (IPILIMUMAB) FOR MELANOMA IN AN ADJUVANT SETTING MEETS PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL
02-Jun-2014 13:34 - BRISTOL-MYERS SQUIBB SAYS PHASE 3 STUDY EVALUATING YERVOY FOR MELANOMA IN ADJUVANT SETTING MEETS PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL
Shares in Peregrine Pharmaceuticals Inc. surged 3.23%, to close the day at $1.92. The stock recorded a trading volume of 2.83 million shares, below its three months average volume of 3.71 million shares. The stock oscillated between $1.86 and $2.00 during the session. Over the last three trading sessions and over the past one month, Peregrine Pharmaceuticals Inc.'s shares have surged 10.98% and 7.87%, respectively. Further, the stock has gained an upside of 38.13% since the start of this year. The stock is trading above its 50-day and
200-day moving averages of $1.85 and $1.61, respectively. Additionally,
Peregrine Pharmaceuticals Inc.'s stock has an RSI of 56.87. Sign up today to
read free research on PPHM at:
http://www.investor-edge.com/3217-PPHM-30May2014.pdf
I hope there are some in europo coming too (soon!)
no news from you today? ibb against pphm :)
i have heard, that a new one came out in May 2014!
old link from 2013:
https://www.citivelocity.com/citigps/OpArticleDetail.action?recordId=209
...very interesting....